Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer

Turk J Med Sci · 2021 · PMC8569782 · PMID 33315355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a review comparing gemcitabine-based regimens, in subgroup analysis, gemcitabine-cisplatin combination had an advantage for survival but it did not reach statistical significance [9].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.